Corporate reports

This report summarises the outcomes of the Pharmacovigilance Inspection Program in the 2-year period. The deficiencies identified are presented along with case studies of critical deficiencies from this reporting period, to support medicine sponsors in the continual improvement of their pharmacovigilance systems.

This report provides information about the TGA’s regulatory performance for the 2024-25 financial year.

Find out about the seasonal influenza vaccines available for the 2026 southern hemisphere season.

We conduct an annual stakeholder survey to improve the way we work with our stakeholders and help report on our key performance indicators.

The report includes data and feedback from the general public (consumers), people and organisations with a TGA business services account (opt-in stakeholders), and state and territory government representatives.

The Australian Sunscreen Exposure Model performs sunscreen exposure calculations that reflect the unique conditions and practices in Australia.

Read our business plan 2025-26 to find out about our strategic priorities and activities.

Documents released under the FOI Act in the 2024/25 financial year

Based on the data considered in this safety review, we recommend regulatory controls for homosalate and oxybenzone to restrict their permitted concentrations and use in therapeutic sunscreens.

This updated safety review uses the Australian Sunscreen Exposure Model to assess the risk of benzophenone as a degradant in sunscreens.

This Cost Recovery Implementation Statement (CRIS) 2025-2026 provides information on how we implement, and cost recover our regulatory activities.